The estimated Net Worth of Kurt M Eichler is at least $715 Tisíc dollars as of 30 December 2019. Kurt Eichler owns over 40,000 units of Spring Bank Pharmaceuticals stock worth over $664,620 and over the last 14 years Kurt sold SBPH stock worth over $50,400.
Sign up
Kurt Eichler SBPH stock SEC Form 4 insiders trading
Kurt has made over 11 trades of the Spring Bank Pharmaceuticals stock since 2010, according to the Form 4 filled with the SEC. Most recently Kurt sold 40,000 units of SBPH stock worth $50,400 on 30 December 2019.
The largest trade Kurt's ever made was buying 76,923 units of Spring Bank Pharmaceuticals stock on 27 June 2017 worth over $999,999. On average, Kurt trades about 7,235 units every 106 days since 2010. As of 30 December 2019 Kurt still owns at least 549,273 units of Spring Bank Pharmaceuticals stock.
You can see the complete history of Kurt Eichler stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kurt Eichler's mailing address?
Kurt's mailing address filed with the SEC is C/O SPRING BANK PHARMACEUTICALS, INC., 35 PARKWOOD DRIVE, SUITE 210, HOPKINTON, MA, 01748.
Insiders trading at Spring Bank Pharmaceuticals
Over the last 9 years, insiders at Spring Bank Pharmaceuticals have traded over $50,400 worth of Spring Bank Pharmaceuticals stock and bought 237,689 units worth $2,510,768 . The most active insiders traders include Todd C Brady, Scott Andrew Smith a Kurt M Eichler. On average, Spring Bank Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $8,517. The most recent stock trade was executed by Garrett Winslow on 19 November 2020, trading 6,250 units of SBPH stock currently worth $7,563.
What does Spring Bank Pharmaceuticals do?
Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.
What does Spring Bank Pharmaceuticals's logo look like?
Complete history of Kurt Eichler stock trades at MiMedx Inc a Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals executives and stock owners
Spring Bank Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Kurt M Eichler,
Director -
Martin J Driscoll,
President and CEO -
David Arkowitz,
Director -
Christiana Bardon,
Director -
Timothy P Clackson,
Director -
Nezam H. Afdhal,
Chief Medical Officer -
Todd C Brady,
Director -
Jonathan Bates,
Director -
Scott Andrew Smith,
Director -
Jonathan Freve,
CFO & Treasurer -
Radhakrishnan P. Iyer,
Chief Scientific Officer -
Garrett Winslow,
General Counsel and Secretary -
Pamela M. Klein,
Director -
Lori Firmani,
VP of Finance and Treasurer